PEDIATRIC LATE OUTCOME PROTOCOL 219

主要目标是纵向跟踪婴儿、儿童和 年参加围产期和儿科ACTG临床试验的青少年 以监测治疗的远期后果，包括长期的 生存和生活质量。在感染艾滋病毒的婴儿和儿童中， 术语“后期结果”一般用来描述长期结果。 可能与艾滋病毒疾病进展、治疗有关的后果 艾滋病毒疾病和治疗的影响和/或相互作用。这是基于 论区分药物效应与疾病效应的理论基础 可能并不总是可能的。将使用“滞后效应”一词 特别是描述抗逆转录病毒治疗的晚期后果 在围产期接受治疗的婴儿中，最终被证明不是 被感染了。围产期接触过药物但未感染的人群提供了 清楚地区分药物和疾病进展之间的机会 效果。

The major aim is to longitudinally follow infants, children, and adolescents enrolled in perinatal and pediatric ACTG clinical trials in order to monitor late consequences of therapy including long-term survival and quality of life. Among HIV-infected infants and children, the term "late outcomes" will be used generically to describe long-term consequences which may be related to HIV disease progression, treatmeent effects and/or an interaction of HIV disease and therapy. This is based on the rationale that distinguishing drug effects from disease effects may not always be possible. The term "late effects" will be used specifically to describe late consequences of antiretroviral therapies among perinatally treated infants who are ultimately proven not infected. The perinatally drug exposed but uninfected group offers the opportunity to cleanly delineate between drug and disease progression effects.